SoelbergKK, BonnemaSJ, BrixTH, HegedüsL. 2012. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid, 22:918–925.
2.
KingD, StackBCJr, SpringP, WalkerR, BodennerD. 2007. Thyroid carcinoma in fluorodeoxyglucose whole body positron emission tomography (PET) positive thyroid “incidentalomas.”Otolaryngol Head Neck Surg, 137:400–404.
3.
RothmanIN, MiddletonL, StackBCJr, RiggsAT, BartelTB, BodennerDL. 2011. The incidence of diffuse fluorodeoxyglucose positron emission tomography (PET) uptake in the thyroid of patients with autoimmune thyroiditis. Eur Arch Otolaryngol, 268:1501–1504.
4.
BoeckmannJ, SiegelE, BartelT, BodennerD, StackBCJr. 2012. Can pathology of a thyroid nodule be determined by PET?Otolaryngol Head Neck Surg, 146:906–912.
5.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. CooperDS, DohertyGM, HaugenBR, KloosRT, LeeSL, MandelSJ, MazzaferriEL, McIverB, PaciniF, SchlumbergerM, ShermanSI, StewardDL, TuttleRM. 2009. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19:1167–1214.
6.
KurataS, IshibashiM, HiromatsuY, KaidaH, MiyakeI, UchidaM, HayabuchiN. 2007. Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET: prevalence of thyroid cancer and Hashimoto's thyroiditis. Ann Nucl Med, 21:325–330.
7.
HollowellJG, StaehlingNW, FlandersWD, HannonWH, GunterEW, SpencerCA, BravermanLE. 2002. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)J Clin Endocrinol Metab, 87:489–499.
